Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.

Kevin WongPriya AryaYansy SalmeronDouglas C BigelowMichael J RuckensteinShubhasree BanerjeeMadhura TamhankarJason A BrantTiffany Peng Hwa

Published in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2024)

Ototoxicity may occur in patients treated with teprotumumab. Hearing loss occurs primarily in higher frequencies, and routine hearing screening with ultrahigh frequency testing may be warranted. The true incidence of ototoxicity with teprotumumab remains unknown, and more data is needed to elucidate underlying mechanisms and develop strategies to minimize risks.

Keyphrases

hearing loss
high glucose
diabetic rats
oxidative stress
risk factors
electronic health record
clinical practice
big data
human health
endothelial cells
risk assessment
data analysis
artificial intelligence
deep learning